Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats

Neuropsychopharmacology

Volumn 39, Issue 2, 2014, Pages 445-455

  Igari, Moe ^a   Alexander, Jon C ^a   Ji, Yue ^a   Qi, Xiaoli ^a   Papke, Roger L ^b   Bruijnzeel, Adrie W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

cytisine; ICSS; nicotine; rats; varenicline; withdrawal

Indexed keywords

CYTISINE; NICOTINE; VARENICLINE; ALKALOID; AZOCINE DERIVATIVE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOLIZINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN DEPTH STIMULATION; DRUG EFFECT; DYSPHORIA; MALE; MOOD; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; REWARD; SMOKING CESSATION; TOBACCO DEPENDENCE; ANIMAL; INFUSION PUMP; PSYCHOLOGICAL ASPECT; WISTAR RAT; WITHDRAWAL SYNDROME;

ALKALOIDS; ANIMALS; AZOCINES; BENZAZEPINES; INFUSION PUMPS, IMPLANTABLE; MALE; NICOTINE; NICOTINIC AGONISTS; QUINOLIZINES; QUINOXALINES; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84890565854     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.216     Document Type: Article

References (64)

1. Alhatem F, Black JE (2009). Varenicline-induced mania in a bipolar patient. Clin Neuropharmacol 32: 117-118.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press: Washington, DC, USA.
3. Barr AM, Markou A, Phillips AG (2002). A 'crash' course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci 23: 475-482.
4. Biala G, Staniak N, Budzynska B (2010). Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn Schmiedebergs Arch Pharmacol 381: 361-370.
5. Bruijnzeel AW (2012). Tobacco addiction and the dysregulation of brain stress systems. Neurosci Biobehav Rev 36: 1418-1441.
6. Bruijnzeel AW, Ford J, Rogers JA, Scheick S, Ji Y, Bishnoi M et al (2012). Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats. Pharmacol Biochem Behav 101: 62-68.
7. Bruijnzeel AW, Prado M, Isaac S (2009). Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawalinduced deficit in brain reward function and stress-induced relapse. Biol Psychiatry 66: 110-117.
8. Bruijnzeel AW, Zislis G, Wilson C, Gold MS (2007). Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 32: 955-963.
9. Changeux JP (2010). Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 11: 389-401.
10. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J et al (2005). Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-3477.
11. Cryan JF, Hoyer D, Markou A (2003). Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54: 49-58.
12. Dani JA, Balfour DJ (2011). Historical and current perspective on tobacco use and nicotine addiction. Trends Neurosci 34: 383-392.
13. Dani JA, Bertrand D (2007). Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47: 699-729.
14. Debruyne D, Sobrio F, Hinschberger A, Camsonne R, Coquerel A, Barre L (2003). Short-term pharmacokinetics and brain distribution of mecamylamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation. J Pharm Sci 92: 1051-1057.
15. Dunnett CW (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50: 1096-1121.
16. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998). Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393: 76-79.
17. Etter JF (2006). Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 166: 1553-1559.
18. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011). Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471: 597-601.
19. Francois D, Odom A, Kotbi N (2011). A case of late-life onset mania during varenicline assisted smoking cessation. Int J Geriatr Psychiatry 26: 658-659.
20. Fudala PJ, Teoh KW, Iwamoto ET (1985). Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol Biochem Behav 22: 237-241.
21. Gourlay SG, Stead LF, Benowitz N (2004). Clonidine for smoking cessation. Cochrane Database Syst Rev 3: Art. No.: CD000058.pub2.
22. Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR Fedorov NB et al (2010). Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*-and alpha 7-nicotine acetylcholine receptors. Neuropharmacology 58: 1054-1066.
23. Harrison AA, Gasparini F, Markou A (2002). Nicotine potentiation of brain stimulation reward reversed by DHbE and SCH 23390 but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) 160: 56-66.
24. Hussain S, Kayne E, Guwanardane N, Petrides G (2011). Varenicline induced mania in a 51 year old patient without history of bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry 35: 1162-1163.
25. Hussmann GP, Turner JR, Lomazzo E, Venkatesh R, Cousins V Xiao Y et al (2012). Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. J Pharmacol Exp Ther 343: 441-450.
26. Jackson KJ, Sanjakdar SS, Muldoon PP, McIntosh JM, Damaj MI (2013). The alpha3beta4*nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the alpha5 subunit in the mouse. Neuropharmacology 70: 228-235.
27. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE et al (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA 296: 56-63.
28. Kenny PJ, Chartoff E, Roberto M, Carlezon WA Jr., Markou A (2009). NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology 34: 266-281.
29. Knibbs N, Tsoi DT (2011). Varenicline induces manic relapse in bipolar disorder. Gen Hosp Psychiatry 33: 641-642.
30. Koob GF, Volkow ND (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
31. Kornetsky C, Esposito RU (1979). Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38: 2473-2476.
32. Kornetsky C, Esposito RU, McLean S, Jacobson JO (1979). Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch Gen Psychiatry 36: 289-292.
33. Kyerematen GA, Owens GF, Chattopadhyay B, deBethizy JD, Vesell ES (1988). Sexual dimorphism of nicotine metabolism and distribution in the rat. Studies in vivo and in vitro. Drug Metab Dispos 16: 823-828.
34. Laine P, Marttila J, Lindeman S (2009). Hallucinations in the context of varenicline withdrawal. Am J Psychiatry 166: 619-620.
35. Le Foll B, Goldberg SR (2005). Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl) 178: 481-492.
36. LeSage MG, Shelley D, Ross JT, Carroll FI, Corrigall WA (2009). Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav 91: 461-467.
37. Leslie FM, Mojica CY, Reynaga DD (2013). Nicotinic receptors in addiction pathways. Mol Pharmacol 83: 753-758.
38. Liu L, Zhao-Shea R, McIntosh JM, Gardner PD, Tapper AR (2012). Nicotine persistently activates ventral tegmental area dopaminergic neurons via nicotinic acetylcholine receptors containing alpha4 and alpha6 subunits. Mol Pharmacol 81: 541-548.
39. Marcinkiewcz CA, Prado MM, Isaac SK, Marshall A, Rylkova D Bruijnzeel AW (2009). Corticotropin-releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats. Neuropsychopharmacology 34: 1743-1752.
40. Markou A, Koob GF (1992). Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51: 111-119.
41. Markou A, Paterson NE (2001). The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res 3: 361-373.
42. May AC, Rose D (2010). Varenicline withdrawal-induced delirium with psychosis. Am J Psychiatry 167: 720-721.
43. McColl SL, Burstein AH, Reeves KR, Billing CB Jr, Stolar M, Sellers EM (2008). Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clin Pharmacol Ther 83: 607-614.
44. Mihalak KB, Carroll FI, Luetje CW (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70: 801-805.
45. Mineur YS, Eibl C, Young G, Kochevar C, Papke RL, Gundisch D et al (2009). Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J Pharmacol Exp Ther 329: 377-386.
46. Museo E, Wise RA (1994a). Place preference conditioning with ventral tegmental injections of cytisine. Life Sci 55: 1179-1186.
47. Museo E, Wise RA (1994b). Sensitization of locomotion following repeated ventral tegmental injections of cytisine. Pharmacol Biochem Behav 48: 521-524.
48. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN Zandi KS et al (2006). Metabolism and disposition of varenicline a selective alpha4beta2 acetylcholine receptor partial agonist in vivo and in vitro. Drug Metab Dispos 34: 121-130.
49. Papke RL, Trocme-Thibierge C, Guendisch D, Al Rubaiy SA Bloom SA (2011). Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists. J Pharmacol Exp Ther 337: 367-379.
50. Papke RL, Wecker L, Stitzel JA (2010). Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 333: 501-518.
51. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI Kellar KJ (2002). Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem 82: 468-481.
52. Picciotto MR, Kenny PJ (2013). Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harb Perspect Med 3: a012112.
53. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH (2003). Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 28: 916-931.
54. Rasmussen T, Swedberg MD (1998). Reinforcing effects of nicotinic compounds: intravenous self-administration in drugnaive mice. Pharmacol Biochem Behav 60: 567-573.
55. Rollema H, Shrikhande A, Ward KM, Tingley FD III, Coe JW O'Neill BT et al (2010). Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 160: 334-345.
56. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC et al (2004). Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65: 1526-1535.
57. Slemmer JE, Martin BR, Damaj MI (2000). Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295: 321-327.
58. Sobieraj DM, White WB, Baker WL (2013). Cardiovascular effects of pharmacologic therapies for smoking cessation. J Am Soc Hypertens 7: 61-67.
59. Spiller K, Xi ZX, Li X, Ashby CR Jr., Callahan PM, Tehim A et al (2009). Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology 57: 60-66.
60. Stokes C, Papke RL (2012). Use of an alpha3beta4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties. Neuropharmacology 63: 538-546.
61. Stolerman IP, Garcha HS, Pratt JA, Kumar R (1984). Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology (Berl) 84: 413-419.
62. Stolerman IP, Jarvis MJ (1995). The scientific case that nicotine is addictive. Psychopharmacology (Berl) 117: 2-10.
63. Toll L, Zaveri NT, Polgar WE, Jiang F, Khroyan TV, Zhou W et al (2012). AT-1001: a high affinity and selective alpha3beta4 nicotinic acetylcholine receptor antagonist blocks nicotine selfadministration in rats. Neuropsychopharmacology 37: 1367-1376.
64. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J Aveyard P et al (2011). Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 365: 1193-1200.